Andrew M. Skinner , Xing Tan , Colin Westman , Thomas Birris , Emily N. Drwiega , Michael S. Wang , Stuart Johnson
{"title":"贝佐托单抗预防多次复发性艰难梭菌感染（CDI）患者复发的疗效。","authors":"Andrew M. Skinner , Xing Tan , Colin Westman , Thomas Birris , Emily N. Drwiega , Michael S. Wang , Stuart Johnson","doi":"10.1016/j.anaerobe.2023.102788","DOIUrl":null,"url":null,"abstract":"<div><p>Among 23 patients with multiply recurrent <em>Clostridiodies difficile</em><span> infection (mrCDI) who received bezlotoxumab<span> at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.</span></span></p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI\",\"authors\":\"Andrew M. Skinner , Xing Tan , Colin Westman , Thomas Birris , Emily N. Drwiega , Michael S. Wang , Stuart Johnson\",\"doi\":\"10.1016/j.anaerobe.2023.102788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Among 23 patients with multiply recurrent <em>Clostridiodies difficile</em><span> infection (mrCDI) who received bezlotoxumab<span> at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.</span></span></p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1075996423000975\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1075996423000975","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI
Among 23 patients with multiply recurrent Clostridiodies difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
